# Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer

> **NCT02924233** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Symphogen A/S**

## Conditions studied

- Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Sym004
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02924233
- **Lead sponsor:** Symphogen A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-11
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Symphogen made a business decision to no longer perform the clinical study
- **Last updated:** 2017-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02924233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02924233, "Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02924233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*